Most pharmacists saw the political headline on May 4th and scrolled past it. That was a mistake. Buried inside a politically polarizing announcement is a concrete reimbursement signal that every pharmacy business owner and clinical pharmacist needs to understand before the billing infrastructure goes live.
What HHS Actually Announced
On May 4, 2026, HHS Secretary Robert F. Kennedy Jr. announced a multipronged action plan at the MAHA Institute Mental Health and Overmedicalization Summit, targeting what the agency calls the overuse of psychiatric medications, particularly SSRIs. The initiative includes education and outreach, program and policy actions, and research-to-practice efforts focused on preventing unnecessary initiation of psychiatric medications and supporting tapering and discontinuation for patients not experiencing clinical benefit.
CMS will issue billing guidance that will allow providers to get paid for deprescribing, including care planning, monitoring withdrawal, coordinating treatment, and tracking outcomes. New Medicare and Medicaid reimbursement pathways are being introduced for clinicians who support patients during psychiatric medication tapering. SAMHSA will release training modules on deprescribing and risk communication. Over 1,400 federally qualified health centers, serving approximately 39 million patients, will receive training on medically supervised tapering for the first time.
A Dear Colleague Letter from HHS, published the same day, acknowledged directly: “Psychiatric medications can play an important and, at times, essential role in treatment. For many individuals, such medications reduce symptoms, improve functioning, prevent relapse, and support recovery.” The letter went on to stress that medications should never be the only option, and it encouraged providers to regularly review risks with patients and engage them in shared decision-making about whether to continue or taper.
The political framing around this announcement is contested. The clinical and business signal inside it is not.
The Scale of the Patient Population
To understand the reimbursement opportunity, start with the patient volume.
Over 16% of American adults currently take antidepressants, 10% of children are on some form of prescription psychiatric medication, 30% of college students have used psychiatric medications in the past year, and over 50% of nursing home residents are on prescription antidepressants. Kennedy framed this as a dependency crisis driven by overmedicalization, noting that “too many patients begin treatment without a clear understanding of the risks and how long they will stay on these drugs or how to come off of them.”
Surveys of antidepressant users suggest 30 to 50% have no evidence-based indication to continue, but coming off antidepressants is often difficult due to fears of relapse, withdrawal symptoms, and a lack of psychological treatments to support the transition.
That number, 30 to 50% of long-term users potentially eligible for a structured medication review and tapering discussion, translates directly into a patient population that is already in your panel, already trusts you, and has never been offered this clinical service by anyone.
The Clinical Science Pharmacists Must Know
Before building a deprescribing service, every pharmacist working in this space needs to understand why standard SSRI tapering protocols fail, and why the pharmacist’s expertise is uniquely suited to do it correctly.
The relationship between SSRI dose and serotonin transporter (SERT) occupancy follows a hyperbolic curve. Reducing a dose from 40 mg to 20 mg may only slightly decrease SERT occupancy, while tapering from 10 mg to 5 mg could result in a 30% drop or more. The most abrupt shifts in receptor occupancy occur at the lowest doses, not the highest. These sudden changes can destabilize mood and cognition, increasing the risk of withdrawal.
This hyperbolic relationship suggests that dose reductions must become progressively smaller as patients approach zero, not remain constant as in a traditional linear taper. Many patients require dose reductions of only 10% of their most recent dose, with tapering potentially taking months to years. Traditional linear tapers are often biologically mismatched, which is why patients report severe withdrawal symptoms that are then misidentified as relapse.
Hyperbolic tapering matches dose reductions to receptor-level change, helping patients tolerate the final and most difficult steps of discontinuation. For SSRIs and SNRIs, liquid formulations or precisely split tablets are often necessary to achieve the small dose reductions required at the lower end of the taper. Bead counting is standard for extended-release venlafaxine. Crushing and suspension is appropriate only for immediate-release formulations, not extended-release capsules, to avoid dose dumping.
This is exactly the kind of formulation-specific, pharmacokinetically grounded clinical work that a PharmD is trained to do and most prescribers are not. No physician writes a prescription for a custom 10% dose reduction using a compounded liquid formulation and monitors the patient through a six-month taper. A pharmacist can build the entire protocol.
What Pharmacists Can Do That No Other Provider Can Replicate
Pharmacists can construct individualized taper schedules, assess drug-drug interactions during dose reduction, watch for serotonin syndrome with concomitant serotonergic agents, and intervene when patients self-discontinue in community settings. Collaborative practice agreements further expand the pharmacist’s role, enabling participation in dose adjustments and deprescribing efforts under physician supervision. In community settings, pharmacists may identify patients attempting to discontinue medications independently and prevent relapse or complications before they escalate.
The serotonin syndrome piece deserves specific attention. Patients who are tapering an SSRI while still taking tramadol, linezolid, triptans, dextromethorphan, or other serotonergic agents carry significant interaction risk during the reduction phase. The prescriber writing the taper order may not track every concomitant medication in the patient’s profile. The pharmacist dispensing every drug in that profile absolutely does.
Consensus guidance supports at least annual formal review of psychopharmacology, and this task requires pharmacist consultation as interaction profiles shift during tapering. The pharmacist’s role extends beyond constructing the taper to monitoring adherence, identifying early discontinuation syndrome symptoms, and coordinating with prescribers when the clinical picture changes.
The Professional Balance the Profession Must Hold
This newsletter covers this story because it contains a clinical and business signal worth acting on. It does not endorse the political framing around psychiatric medication use, and it is important for pharmacists to hold this professional balance clearly.
Professional organizations have urged caution regarding broad claims of SSRI overprescribing. Dr. Jonathan Alpert, Chair of Psychiatry at Montefiore Medical Center, put it plainly: “We should be concerned about both overprescribing and underprescribing. In some instances, psychiatric medications are overprescribed and cause unnecessary side effects, cost, and other harms. In many other instances, they are lifesaving.”
The American Psychiatric Association stated that real issues include access, workforce shortages, and uneven quality of care, arguing that “deprescribing alone is not a sufficient response.” The organization noted it supports the administration’s plans for investment and clinical training, while objecting to framing the mental health crisis primarily as a problem of overmedicalization.
The pharmacist entering this clinical space does so with a clear mandate: individualized care, evidence-based tapering science, and active monitoring for harm. The service exists to support patients who, in shared decision-making with their prescriber, choose to attempt discontinuation. It does not exist to push patients off medications they need.
Building the Clinical Protocol Now
The CMS billing guidance is coming. The training webinars launch in June and July. The expert panel convenes in July to draft formal clinical guidance. The billing infrastructure is being built in real time, and the pharmacists who have a clinical protocol already in place when the guidance finalizes will be the ones positioned to bill for it from day one.
Here is what a pharmacist-led psychiatric medication review and deprescribing service requires:
The patient identification step. Review your panel for patients on long-term SSRI or SNRI therapy, two years or more, with no documented medication review in the past 12 months. These patients are the starting population for a structured outreach program.
The clinical assessment framework. Has the patient’s original indication been reassessed? Is there a documented clinical reason for continued long-term use? Has the patient ever expressed interest in tapering? A structured clinical conversation, built around these questions, constitutes the medication review service that CMS billing will support.
The taper protocol infrastructure. Know how to generate a hyperbolic taper schedule for the five most dispensed SSRIs in your patient panel. Understand which formulations support precise dose reduction and which require compounding or liquid preparation. Build a monitoring schedule that includes check-ins at weeks 2, 4, 8, and at each dose step.
The collaborative practice agreement foundation. A CPA with a prescriber formalizes the pharmacist’s authority to adjust doses within a defined taper protocol without a new prescription for each step. Without this agreement, the pharmacist is advising. With it, the pharmacist is executing the clinical plan, which is the billable service.
The Bottom Line
CMS is building payment infrastructure for psychiatric medication tapering and monitoring. SAMHSA is building training infrastructure across 39 million patient touchpoints at federally qualified health centers. HHS has explicitly acknowledged that regular review of psychiatric medication risks with patients is a reimbursable clinical activity.
The pharmacist is the most qualified clinician in the American healthcare system to deliver this service. No other provider combines the formulation expertise, the interaction surveillance capability, the community access, and the longitudinal patient relationship that a pharmacist brings to a six-month SSRI taper.
Build the protocol now. The billing code is being written for exactly what you already know how to do.
Sources: HHS Press Release (MAHA Action Plan to Curb Psychiatric Overprescribing, May 4, 2026), Pharmacy Times (Announcing New Initiatives, RFK Jr. Continues Push for Americans to Discontinue Antidepressants, May 2026), NPR (RFK Jr.’s Plan for Antidepressants Gets Mixed Reaction from Psychiatrists, May 2026), CNN (RFK Jr. Launches Plan to Curb Overprescribing of Psychiatric Drugs, May 2026), The Federalist (CMS Billing Guidance for Deprescribing Coverage), PMC / Therapeutic Advances in Psychopharmacology (Clinical Practice Guideline Recommendations on Tapering and Discontinuing Antidepressants), Psychopharmacology Institute (Hyperbolic Tapering of Antidepressants: Clinical Evidence, September 2025), Carlat Geriatric Psychiatry Report (Clinical Pearls for Hyperbolic Tapering in Older Adults, February 2026), ACCP (TAPER Pharmacist-Led Pilot RCT Protocol), ResearchGate / Therapeutic Advances in Psychopharmacology (Hyperbolic Tapering of Antidepressants: Where Are We Now, January 2026)